Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
natalina.elliott@paediatrics.ox.ac.uk

Telephone
+44 1865 222419

ORCID
https://orcid.org/0000-0002-6713-7349

Research groups

Natalina Elliott

PhD-Cancer Biology, Vanderbilt University; BS-Recombinant Genetics & Chemistry, Western Kentucky University

Postdoctoral Researcher

Recent publications

Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.

Ren H. et al, (2026), Blood, 147, 180 - 196

Bi-specific CAR-iNKT cell immunotherapy for high-risk KMT2A-rearranged leukemia outperforms CAR-T in an NKG2D-dependent manner and eradicates leptomeningeal disease

Ren H. et al, (2025)

The Fetal Specific Gene LIN288 Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Ling RE. et al, (2024), BLOOD, 144, 199 - 200

The genome-wide impact of trisomy 21 on DNA methylation and its implications for hematopoiesis.

Muskens IS. et al, (2021), Nat Commun, 12

Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.

Louka E. et al, (2021), J Exp Med, 218

More publications